Please login to the form below

Not currently logged in
Email:
Password:

Orphan Drug

Sponsored by

Finalist

Osteosarcoma - rewriting the rule book

Takeda UK in association with Liberation Communications


Summary of work

Mepact (mifamurtide), the first therapeutic advance for more than 20 years, has been developed for osteosarcoma, a very rare form of bone cancer. It is a highly aggressive cancer with a propensity to metastasise, affecting around 150 children and young adults each year across the UK. 

Before Mepact was available a third of all children and young adults diagnosed with osteosarcoma did not survive. With Mepact it is estimated that an additional 12 children across the UK will survive osteosarcoma each year and go on to live ‘normal’ long lives. Mepact was submitted to NICE for a technical appraisal and despite a Patient Access Scheme (PAS) being proposed by Takeda, both NICE and the SMC gave initial negative decisions in July 2010. 

Takeda worked with the Department of Health, NICE and the SMC to find a solution. After three further appraisal committee meetings, NICE acknowledged that to accurately assess the health economic value of Mepact, it would need to change its methodology to assess medicines that improve survival rates beyond 30 years. 

Following a fifth appraisal committee meeting a positive decision about the use of Mepact was given. The SMC also reversed its initial negative decision to recommend that Mepact could also be prescribed in Scotland. 

 

 

Executive summary as submitted


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics